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Abstract
Background: Response-adaptive randomizations are able to assign more patients in a comparative clinical trial to
the tentatively better treatment. However, due to the adaptation in patient allocation, the samples to be compared
are no longer independent. At large sample sizes, many asymptotic properties of test statistics derived for
independent sample comparison are still applicable in adaptive randomization provided that the patient allocation
ratio converges to an appropriate target asymptotically. However, the small sample properties of commonly used
test statistics in response-adaptive randomization are not fully studied.
Methods: Simulations are systematically conducted to characterize the statistical properties of eight test statistics
in six response-adaptive randomization methods at six allocation targets with sample sizes ranging from 20 to 200.
Since adaptive randomization is usually not recommended for sample size less than 30, the present paper focuses
on the case with a sample of 30 to give general recommendations with regard to test statistics for contingency
tables in response-adaptive randomization at small sample sizes.
Results: Among all asymptotic test statistics, the Cook’s correction to chi-square test (TMC) is the best in attaining
the nominal size of hypothesis test. The William’s correction to log-likelihood ratio test (TML) gives slightly inflated
type I error and higher power as compared with TMC, but it is more robust against the unbalance in patient
allocation. TMC and TML are usually the two test statistics with the highest power in different simulation scenarios.
When focusing on TMC and TML, the generalized drop-the-loser urn (GDL) and sequential estimation-adjusted urn
(SEU) have the best ability to attain the correct size of hypothesis test respectively. Among all sequential methods
that can target different allocation ratios, GDL has the lowest variation and the highest overall power at all
allocation ratios. The performance of different adaptive randomization methods and test statistics also depends on
allocation targets. At the limiting allocation ratio of drop-the-loser (DL) and randomized play-the-winner (RPW) urn,
DL outperforms all other methods including GDL. When comparing the power of test statistics in the same
randomization method but at different allocation targets, the powers of log-likelihood-ratio, log-relative-risk, log-
odds-ratio, Wald-type Z, and chi-square test statistics are maximized at their corresponding optimal allocation ratios
for power. Except for the optimal allocation target for log-relative-risk, the other four optimal targets could assign
more patients to the worse arm in some simulation scenarios. Another optimal allocation target, RRSIHR, proposed
by Rosenberger and Sriram (Journal of Statistical Planning and Inference, 1997) is aimed at minimizing the number
of failures at fixed power using Wald-type Z test statistics. Among allocation ratios that always assign more patients
to the better treatment, RRSIHR usually has less variation in patient allocation, and the values of variation are
consistent across all simulation scenarios. Additionally, the patient allocation at RRSIHR is not too extreme. Therefore,
RRSIHR provides a good balance between assigning more patients to the better treatment and maintaining the
overall power.
Conclusion: The Cook’s correction to chi-square test and Williams’ correction to log-likelihood-ratio test are generally
recommended for hypothesis test in response-adaptive randomization, especially when sample sizes are small.
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Background
The response-adaptive randomization (RAR) in clinical
trials is a class of flexible ways of assigning treatment to
new patients sequentially based on available data. The
RAR adjusts the allocation probabilities to reflect the
interim results of the trial, thereby allowing patients to
benefit from the interim knowledge as it accumulates in
the trial. In practice, unequal allocation probabilities are
generated based on the current assessment of treatment
efficacy, which results in more patients being assigned
to the treatment that is putatively superior.
Many RAR designs have been proposed over the years
[1-13]. The two key issues extensively investigated are
the evaluations of parameter estimations and hypothesis
testing. Due to the dependency of assigning new
patients based on observed data at that time, conven-
tional estimates of treatment effect are often biased;
therefore, efforts have been made to quantify and cor-
rect estimation bias [14,15]. Recent theoretical works
have been focused on solving problems encountered in
practice, which includes delayed response, implementa-
tion for multi-arm trials, and incorporating covariates,
etc. [1,3,11,16-18]. Many recent theoretical develop-
ments are summarized in [19]. Additionally, in order to
compare treatment efficacies through hypothesis testing,
studies have been conducted on power comparisons and
sample size calculations under the framework of adap-
tive randomization [20-24]. However, most of the works
are based on large sample sizes, and focus on asymptotic
properties [4,12,22,25,26]. But these properties have not
been fully studied with small sample sizes. The mathe-
matical challenge imposed by correlated data makes it
extremely difficult to derive exact solutions for finite
samples. Up to now, only limited results on exact solu-
tions have been available [15,27], and computer simula-
tion has to be relied upon when sample size is small
[23,24], which is often the case in early phase II trials.
Each RAR design has its own objective, and there are
both advantages and disadvantages associated with that
objective. It is not our purpose to give a comprehensive
assessment of different designs by comparing their
advantages and disadvantages. Instead, the primary
objective of the present study is to characterize the
small sample properties of RAR based on a frequentist
approach. In particular, we focus on comparing the per-
formance of commonly used test statistics in RAR of
two-arm comparative trials with a binary outcome. Due
to the departure from normality caused by data correla-
tion and the discrete nature of a binary outcome,
hypothesis tests usually can not be controlled at any
given levels of nominal significance. Thus, to make our
simulation comparison more relevant, our assessment of
hypothesis testing methods and RAR procedures is
based on the calculation of both statistical power and
the comparison to the nominal type I error rate. Several
RAR methods studied in our simulations can assign
patients according to a given allocation target, which
may be optimal in terms of maximizing the power or
minimizing the expected treatment failure. Therefore,
we also compare the properties of test statistics at differ-
ent optimal allocation targets.
The remaining parts of this paper are organized into
4 sections. In the Methods Section, we introduce the
adaptive randomization procedures, the optimal alloca-
tion rates, and the test statistics used in the simulation.
In the Results Section, we present the simulation results.
We provide a discussion and final recommendations
regarding the RAR methods and hypothesis tests in the
Discussion and Conclusions Sections.
Methods
I nt h ep r e s e n ts e c t i o n ,w eb r i e f l yd e s c r i b et h er a n d o m i -
zation methods, asymptotic hypothesis test statistics,
and optimal patient allocation targets that are relevant
to our simulations. More detailed information can be
found in the corresponding references.
Response-based Adaptive Randomization (RAR)
The RAR procedures investigated in the present study
are randomized play-the-winner (RPW) [8,10], drop-the-
loser (DL) [28], sequential maximum likelihood estima-
tion (SMLE) [12], doubly-adaptive biased coin [2,3],
sequential estimation-adjusted urn (SEU) [13], and gen-
eralized drop-the-loser (GDL) [11] designs. RPW, DL,
SEU and GDL are all urn models in the sense that treat-
ment assignment for each patient can be obtained by
sampling balls from an urn. In the usual clinical trial
setting, an urn model consists of one urn with different
types of balls that represent the different treatments
under study. Patients are assigned to treatments by ran-
domly selecting balls from the urn. Initially, the urn
contains an equal number of balls for each of the treat-
ment offered in the trial. With the progress of a clinical
trial, certain rules are applied to update the contents of
the urn in such a way that favors the selection of balls
corresponding to the better treatment. For example,
under the RPW design, the observation of a successful
treatment response leads to the addition of a (>0) balls
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Page 2 of 14of the same type to the urn; a lack of success leads to
the addition of b (>0) balls of the other type to the urn
(a = b = 1 in our simulation). The limiting allocation
rate of patients on treatment 1 is q2/(q1 + q2), where
q1 =1 - p1 and q2 =1 - p2 are failure rates, and p1 and p2
are success rates (or response rates) for treatments 1
and 2. In the DL model, patients are assigned to a treat-
ment based on the type of ball that is drawn; however a
treatment failure results in the removal of a treatment
ball from the urn, and treatment successes are ignored.
Due to the finite probabilities of extinction, immigration
balls are added to the urn. If an immigration ball is
drawn, an additional ball of each type is added. The
sampling process is repeated until a treatment ball is
drawn. The DL urn design has the same limiting alloca-
tion as the RPW urn, but less variability in patient allo-
cation. Both SEU and GDL are urn models allowing
fraction number of balls, and can target any allocation
rate. For SEU method [13], if the limiting allocation of
RPW urn is the target in a two-arm trial, then
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balls of type 1 are added to the urn following the alloca-
tion of the ith patient. Obviously, the response status of
the ith patient is related to the contents of SEU urn
only through the calculation of qi
∧ () 1 and qi
∧ () 2 .F o r
a two-arm GDL urn model [11], when a treatment ball
is drawn, a new patient is assigned accordingly, but the
ball will not be returned to the urn. Depending on the
response of the patient, the conditional average numbers
of balls being added back to the urn are b1 and b2 for
treatments 1 and 2, respectively. Therefore, the condi-
tional average numbers of type 1 and type 2 balls being
taken out of the urn can be defined as d1 and d2,w h e r e
d1 =1 - b1 and d2 =1 - b2. Immigration balls are also pre-
sent in a GDL urn. Whenever an immigration ball is
drawn, a1 and a2 balls are added for treatments 1 and 2,
respectively. Zhang et al [11] have shown that the limit-
ing allocation rate of patients on treatment 1 is
n
n
a
d
a
d
a
d
1
1
1
1
1
2
2
→
+
. (1)
The GDL urn becomes a DL urn when a1 =1 ,a2 =1 ,
b1 = p1,a n db2 = p2. Although GDL is a general method
with different ways of implementation, a convenient
approach is taken in our simulation. When a treatment
ball is drawn, the ball is not returned, and no ball is added
regardless of the response of the patient. When an immi-
gration ball is drawn, Cr1 and Cr2 balls of type 1 and 2 are
added, where C is a constant, and r1 and r2 are allocation
targets on treatments 1 and 2, which are estimated sequen-
tially using the maximum likelihood estimates (MLE) [11].
The SMLE and doubly-adaptive biased coin design
(DBCD) methods can also target any allocation ratios,
and SMLE can be implemented as a special case of
DBCD method. In DBCD method, the probability of the
(i+1)th patient being assigned to treatment 1 is calcu-
lated by
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where r1 = n1(i)/i and r(i) are the current allocation
rate and estimated allocation rate on treatment 1 [2,3].
The properties of the DBCD depend largely on the
selection of g, which can be considered as a measuring
function for the deviation from the allocation target.
In the present study, we use the following function
suggested by Hu and Zhang [3]:
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where a is a tuning parameter. When a approaches
infinity, the DBCD becomes deterministic and the
patients are assigned to the putatively better treatment
with probability 1. When a equals to 0, the MLE of
r becomes the allocation target, and the DBCD method
is essentially the same as the SMLE design proposed by
Melfi et al [12].
Hypothesis Tests for Two-Arm Comparative Trials
In two-arm comparative trials, the results of a binary
outcome variable can be summarized in a 2 × 2 contin-
gency table (Table 1). The following hypothesis test is
often conducted to compare treatment efficacy:
Hp p
Hp p
01 2
11 2
:
:
.
=
≠
(4)
Nine test statistics for the hypothesis test in (4) are
given in Table 2. When relative risk (q1/q2) and odds ratio
Table 1 Summary of data from a two-arm comparative
clinical trial
Response Failure Margins
Treatment 1 r1 f1 n1
Treatment 2 r2 f2 n-n1 = n2
Margins r1 + r2 = rn -r = f1 + f2 = fn
n: total number of patients; n1, n2: patients on treatment 1 and 2; r: total
number of treatment successes; r1, r2: number of successes on treatment 1
and 2.
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treatment arms, the test statistics are log-relative-risk and
log-odds-ratio, TRisk and TOdds, which are asymptotically
distributed as chi-square distribution with one degree of
freedom ( 1
2). When simple difference is used to measure
the treatment effect, the applicable test statistics are the
Wald-type test statistic TWald and the score-type test sta-
tistics TChisq,w h e r et h ev a r i a n c eo fs i m p l ed i f f e r e n c ei n
response rates is evaluated at H1 or H0 respectively. Addi-
tionally, the test statistics based on the logarithm of likeli-
hood ratio (TLLR) can also be constructed. Besides the
5 commonly used test statistics mentioned above, four
modified test statistics are also included in Table 2. TMO is
a modified log-odds-ratio test proposed by Gart using the
approximation of discrete distributions by their continu-
o u sa n a l o g u e s[ 2 9 ] .A ss h o w ni nT a b l e2 ,TMO is essen-
tially a modification to TOdds by adding 0.5 to each cell of
a 2 × 2 table. Similarly, Agresti and Caffo proposed a mod-
ification to TWald by adding 1 to each cell of a contingency
table [30], which results in the test statistic TMW in Table
2. TMC is the Cook’s continuity correction to chi-square
test statistics TChisq. Williams provided a modification to
log-likelihood-ratio test TLLR [31]. The original test statis-
tic TLLR is improved by multiplying a scale factor such
that the null distribution of the new test statistic TML has
the same moments as the chi-square distribution.
Since all test statistics in Table 2 are based on 1
2,
they are asymptotically equivalent and any one of them
can be used for large sample sizes. Meanwhile at small
sample sizes, an exact test can be conducted if a model
is specified for the data given in Table 1. For example,
depending on the number of fixed margins predeter-
mined for the design, one of the following three models
can be applied [32]:
Pr | , , | , , , rn n r h rn n r 11 11 () = () (5)
Pr , | , , | , , | , , rrn np hr n nrbrn p 11 1 1 () = () ( ) (6)
and
Pr , , | , ,
|, , |, |, ,
rr n n p
hr n nrbrn pbn n p
11
11 1
 ()
= () ( ) ( )
(7)
where h(r1|n, n1, r) represents the hypergeometric dis-
tribution of r1, b(r|n, p) gives the binomial distribution
of r under the null hypothesis of equal response rates
(H0: p1 = p2 = p), and b(n1|n, r) denotes the binomial
distributions of patients on arm 1 with an allocation
ratio of r (r1 = 0.5 for equal randomization). The p
value of exact test can be calculated by maximizing the
probability in (5), (6), or (7) over the two nuisance para-
meters, p and r. However, due to data dependency,
none of the above three models are directly applicable
in adaptive randomization. For example, the allocation
ratio r in adaptive randomization is a random variable
with unknown distribution, and the binomial distribu-
tion of n1 assumed in model (7) is not valid even when
the null hypothesis is true. Therefore, in adaptive rando-
mization, unconditional exact tests are not available and
asymptotic test statistics such as the ones in Table 2 are
required for testing the hypothesis in (4).
Optimal Allocation Ratios
The SMLE, DBCD, SEU, and GDL methods can be uti-
lized to allocate patients based on different allocation
targets. The allocation targets simulated in the present
study are summarized in Table 3, where RRisk, ROdds,
RWald, RChisq,a n dRLLR are optimal allocation ratios
maximizing the power of TRisk, TOdds, TWald, TChisq,a n d
TLLR respectively, at fixed sample size. The derivation of
TRisk, TOdds, TWald, TChisq,a n dTLLR can be found in
[33,34], which is equivalent to minimizing the variance
of corresponding test statistic at a fixed total sample
size, and consequently the power of that test statistic is
maximized. RRSIHR is a recently proposed allocation tar-
get that minimizes the expected total number of failures
among all trials with the same power [15,33]. The
Table 2 Test statistics
Log-relative-risk TRisk = (log(f2n1/f1n2))
2/(r1/n1f1 + r2/n2f2)
Log-odds-ratio TOdds = (log(f2 r1/f1 r2))
2/(1/f1 +1 / f2 +1 / r1 + 1/r2)
Wald-type Z Tr n r n f r n f r n Wald =− () + () 1122
2
21 1
3
12 2
3 // / / /
Chi-square TChisq =( n -1 )( r1f2 - r2f1)
2/rfn1n2
Log-likelihood-ratio TLLR = 2·(r1 log r1 + r2 log r2 + f1 log f1 + f2 log f2 - r log r- f log f - n1 log n1 - n2 log n2 + n log n)
Gart’s correction to TOdds [29] TMO = (log (f’2n’1/f’1n’2))
2/(r’1/n’1f’1 + r’2/n’2f’2)
Agresti’s correction to TWald Tr n r nf r n f r n MW = ′′ ′′ − ′′ ′′ () ′′ ′′ ′′ + ′′ ′ ′ ′ () 112 2
2
21 1
3
12 2
3 // / / /
Cook’s correction to TChisq TMC =( n - 1)(|r1f2 - r2f1|- 0.5)
2/rfn1n2
William’s correction to TLLR [31] TML =[ 1+( n2 - rf)(n2 - n1n2)/6rfn1n2n]
-1·TLLR
r’1 = r1 + 0.5, r’2 = r2 + 0.5, f’1 = f1 + 0.5, f’2 = f2 + 0.5, r’ = r +1 ,f’ +1 ,n’1 = n1 +1 ,n’2 = n2 +1 ,n’ = n +2r”1 = r1 +1 ,r”2 = r2 +1 ,f”1 = f1 +1 ,f”2 = f2 +1 ,
r” = r +2 ,f” = f +2 ,n”1 = n1 +2 ,n”2 = n2 +2 ,n” = n +4
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mentation of optimal allocation in k-arm trials with bin-
ary outcomes are discussed and demonstrated by
Tymofyeyev et al [35], where the optimization can be
conducted over different goals. In practice, the perfor-
mance of the methodology depends on the chosen RAR
procedure. The present simulation study only focuses
on two-arm trials, with a goal of maximizing the power
or minimizing the total number of failures.
Results
Simulations are conducted at different total numbers of
patients ranging from 20 to 200. To simplify the presen-
tation, the results for trials with 30 patients are shown
here. When patients are less than 30, adaptive randomi-
zation is generally not recommended. For sample size of
100 or larger, all methods yield similar properties in
general. For all of the urn models, one ball for each
treatment is consistently used as the initial contents of
the urn. The number of immigration balls is 1 for both
the DL and GDL urns. The tuning parameter of DBCD,
a, is fixed at 0 or 2. When a is 0, it results in the SMLE
method. The value of the constant C in GDL is 2, which
is equivalent to adding 2 treatment balls on average
when an immigration ball is drawn. All simulation
results are calculated based on 10,000 replicates.
For the purpose of comparison, the true allocation
rates are shown in Table 4, and the simulated results for
allocation rates on arm 1 are shown in Table 5. Among
all RAR methods, DBCD has the best ability to attain
the true allocation target. The comparison between
SMLE and DBCD shows that, the allocation becomes
more unbalanced and the variation of DBCD decreases
with increasing value of tuning exponent a.O nt h e
other hand, the patient allocation of SEU results in
more balanced mean allocation between two arms with
a much larger variation as compared with other RAR
methods. The GDL has the lowest variation among the
four sequential RAR methods. When RRPW (the same as
RDL) is the allocation target, DL urn method has the
lowest variation in patient allocation, which is consistent
with the fact that the lower bound of the estimate of
Var(RRPW) is attained by DL urn [4]. The comparison
among allocation targets shows that RLLR has the lowest
variation in patient allocation, and the highest variation
is usually found at RRPW or RRisk.H o w e v e r ,RRPW and
RRisk are usually the top two allocation targets that
assign more patients to the better treatment. RWald,
ROdds, and RLLR assigns more patients to the worse arm
in some simulation cases. Among the three allocation
targets that assign more patients to the better treatment
(RRSIHR, RRisk and RRPW), RRSIHR has a stable and often
the lowest variation in patient allocation.
The simulation results are obtained for five null cases
and ten alternative cases, and Table 6 gives the sum-
mary by averaging the results over the five null cases
and the ten alternative cases for a given RAR method
and at a given allocation target. Detailed simulation
results for each test statistic are shown in Tables 7, 8, 9,
10, 11, 12 with one table for each of the six allocation
targets. To simplify the presentation, the results are
shown only for the four modified test statistics TMW,
TMO, TMC, TML,a n dt h el o g - r e l a t i v e - risk test statistic
TRisk because they tend to have better performance than
the four corresponding unmodified tests. The qualitative
comparisons among test statistics, RAR methods, and
allocation targets can be made based on the results in
Table 6.
As shown in Table 6 (also see Tables 7, 8, 9, 10, 11,
12), the worst performance can be found in the results
of TMO and TRisk, which are often conservative with less
than nominal type I error rate. TMW is always slightly
conservative across all simulation cases. Overall, TMC is
Table 3 Allocation targets
Optimal allocation ratio (n1/n2) for maximizing powers
RRisk pq pq 12 21 /
ROdds /RChisq pq pq 22 11 /
RWald /RNeyman pq pq 11 22 /
RLLR {q2 - p2 exp[I1 - I2/(p2 - p1)]}/{-q1 + p1 exp[I1 - I2/(p2 - p1)]}
Other allocation targets
RRPW/RDL q2/q1
RRSIHR pp 12 / (Minimize the number of failure at fixed
power of TWald)
I1 = p1 log(p1)+q1 log (q1), I2 = p2 log(p2)+q2 log(q2)
Table 4 Asymptotic allocation rates on arm 1 calculated from true p1 and p2
p1 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
RWald /RNeyman 0.396 0.375 0.396 0.500 0.478 0.500 0.604 0.522 0.625 0.604
RRisk 0.337 0.250 0.179 0.100 0.396 0.300 0.179 0.396 0.250 0.337
ROdds /RChisq 0.604 0.625 0.604 0.500 0.522 0.500 0.396 0.478 0.375 0.396
RLLR 0.534 0.538 0.528 0.500 0.507 0.500 0.472 0.493 0.462 0.466
RRSIHR 0.366 0.309 0.274 0.250 0.436 0.396 0.366 0.458 0.427 0.469
RRPW /RDL 0.438 0.357 0.250 0.100 0.417 0.300 0.125 0.375 0.167 0.250
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Page 5 of 14Table 5 Mean and standard deviation (in parenthesis) of allocation rate on arm 1 for n =3 0
Null p1 0.2 0.3 0.5 0.7 0.8
p2 0.2 0.3 0.5 0.7 0.8
Urn RPW 0.500(0.081) 0.500(0.095) 0.500(0.129) 0.500(0.179) 0.500(0.209)
DL 0.500(0.048) 0.500(0.058) 0.500(0.078) 0.500(0.092) 0.500(0.097)
SMLE RWald 0.500(0.106) 0.500(0.103) 0.500(0.098) 0.500(0.103) 0.500(0.106)
RRisk 0.500(0.130) 0.500(0.134) 0.500(0.140) 0.500(0.151) 0.500(0.158)
ROdds 0.500(0.109) 0.500(0.098) 0.500(0.091) 0.500(0.099) 0.500(0.109)
RLLR 0.500(0.093) 0.500(0.092) 0.500(0.091) 0.500(0.093) 0.500(0.094)
RRSIHR 0.500(0.117) 0.500(0.116) 0.500(0.109) 0.500(0.106) 0.500(0.102)
RRPW 0.500(0.100) 0.500(0.109) 0.500(0.131) 0.500(0.166) 0.500(0.192)
DBCD RWald 0.500(0.090) 0.500(0.075) 0.500(0.055) 0.500(0.075) 0.500(0.090)
RRisk 0.500(0.126) 0.500(0.124) 0.500(0.123) 0.500(0.127) 0.500(0.140)
ROdds 0.500(0.082) 0.500(0.061) 0.500(0.047) 0.500(0.061) 0.500(0.082)
RLLR 0.500(0.049) 0.500(0.046) 0.500(0.044) 0.500(0.047) 0.500(0.049)
RRSIHR 0.500(0.107) 0.500(0.099) 0.500(0.078) 0.500(0.060) 0.500(0.054)
RRPW 0.500(0.064) 0.500(0.074) 0.500(0.104) 0.500(0.148) 0.500(0.185)
SEU RWald 0.500(0.113) 0.500(0.106) 0.500(0.098) 0.500(0.106) 0.500(0.114)
RRisk 0.500(0.155) 0.500(0.168) 0.500(0.195) 0.500(0.223) 0.500(0.237)
ROdds 0.500(0.101) 0.500(0.104) 0.500(0.130) 0.500(0.176) 0.500(0.196)
RLLR 0.500(0.093) 0.500(0.091) 0.500(0.091) 0.500(0.093) 0.500(0.092)
RRSIHR 0.500(0.149) 0.500(0.146) 0.500(0.131) 0.500(0.116) 0.500(0.106)
RRPW 0.500(0.135) 0.500(0.155) 0.500(0.192) 0.500(0.222) 0.500(0.233)
GDL RWald 0.500(0.056) 0.500(0.046) 0.500(0.033) 0.500(0.047) 0.500(0.056)
RRisk 0.500(0.106) 0.500(0.114) 0.500(0.128) 0.500(0.144) 0.500(0.154)
ROdds 0.500(0.040) 0.500(0.035) 0.500(0.055) 0.500(0.090) 0.500(0.112)
RLLR 0.500(0.029) 0.500(0.026) 0.500(0.024) 0.500(0.026) 0.500(0.029)
RRSIHR 0.500(0.073) 0.500(0.070) 0.500(0.058) 0.500(0.045) 0.500(0.039)
RRPW 0.500(0.053) 0.500(0.065) 0.500(0.088) 0.500(0.116) 0.500(0.133)
Alternative p1 0.1 0.1 0.1 0.1 0.3
p2 0.3 0.5 0.7 0.9 0.5
Urn RPW 0.444(0.080) 0.375(0.092) 0.287(0.096) 0.181(0.088) 0.430(0.109)
DL 0.447(0.046) 0.383(0.055) 0.316(0.056) 0.249(0.053) 0.437(0.067)
SMLE RWald 0.440(0.100) 0.424(0.098) 0.441(0.100) 0.501(0.102) 0.483(0.101)
RRisk 0.397(0.117) 0.325(0.107) 0.259(0.095) 0.186(0.079) 0.415(0.133)
ROdds 0.562(0.110) 0.577(0.107) 0.561(0.110) 0.499(0.126) 0.517(0.095)
RLLR 0.519(0.094) 0.522(0.094) 0.515(0.094) 0.499(0.095) 0.506(0.092)
RRSIHR 0.417(0.108) 0.369(0.100) 0.335(0.093) 0.312(0.087) 0.447(0.112)
RRPW 0.447(0.099) 0.384(0.105) 0.297(0.106) 0.179(0.091) 0.434(0.117)
DBCD RWald 0.417(0.081) 0.393(0.073) 0.416(0.081) 0.499(0.095) 0.475(0.065)
RRisk 0.371(0.106) 0.285(0.086) 0.216(0.071) 0.138(0.054) 0.394(0.116)
ROdds 0.585(0.085) 0.607(0.078) 0.586(0.086) 0.499(0.110) 0.520(0.053)
RLLR 0.474(0.048) 0.468(0.046) 0.477(0.047) 0.500(0.047) 0.493(0.045)
RRSIHR 0.392(0.093) 0.332(0.077) 0.297(0.069) 0.273(0.063) 0.431(0.088)
RRPW 0.440(0.063) 0.366(0.072) 0.266(0.078) 0.129(0.064) 0.422(0.087)
SEU RWald 0.476(0.113) 0.464(0.110) 0.473(0.113) 0.505(0.117) 0.493(0.104)
RRisk 0.433(0.143) 0.361(0.130) 0.296(0.115) 0.234(0.091) 0.440(0.166)
ROdds 0.514(0.108) 0.497(0.124) 0.462(0.143) 0.388(0.137) 0.489(0.119)
RLLR 0.510(0.093) 0.512(0.094) 0.508(0.093) 0.501(0.094) 0.503(0.092)
RRSIHR 0.461(0.143) 0.425(0.130) 0.402(0.122) 0.383(0.113) 0.475(0.136)
RRPW 0.469(0.129) 0.424(0.136) 0.367(0.135) 0.294(0.113) 0.462(0.164)
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Page 6 of 14the best in attaining the correct type I error rate. TML,i s
slightly inflated as compared with chi-square test TMC.
However, the simulation results not shown here indicate
that TML is very robust against the unbalance in patient
allocation even when sample size is 20. The comparison
between different RAR methods shows that the mean
type I error of GDL and SEU can usually match the cor-
rect size of tests better than other methods when TMC
and TML are used respectively. The type I error of
DBCD is usually the largest one, except at ROdds.T h e
overall type I error of SEU is comparable with GDL.
The power comparison of different test statistics indi-
cates that TRisk is the statistic with the highest power at
RRisk but with a much inflated type I error. Except at
RRisk, TMC or TML is the one with the highest power.
Usually, GDL has the highest power and SEU has the
lowest power among all RAR methods. DBCD and
SMLE have similar power, but DBCD is more powerful
in most cases. At target RRPW, DL urn has the best sta-
tistical properties. On the average, the target with the
lowest power achieved by test statistics is RRisk.T h e
highest overall power can usually be achieved by test
statistics at RRSIHR and RLLR,b u tRLLR has the disadvan-
tage of assigning more patients to the worse treatment
in some cases.
Discussion
In response-adaptive randomization, the assignment of a
new patient depends on the treatment outcomes of
patients previously enrolled in the trial. Delayed
responses are often encountered in practice. Recently,
the problem of delayed response in multi-arm
Table 5: Mean and standard deviation (in parenthesis) of allocation rate on arm 1 for n =3 0(Continued)
GDL RWald 0.450(0.051) 0.437(0.046) 0.452(0.051) 0.500(0.058) 0.486(0.040)
RRisk 0.397(0.093) 0.320(0.085) 0.251(0.071) 0.181(0.055) 0.407(0.114)
ROdds 0.527(0.043) 0.508(0.053) 0.454(0.072) 0.341(0.080) 0.484(0.045)
RLLR 0.517(0.027) 0.521(0.026) 0.515(0.027) 0.500(0.028) 0.505(0.024)
RRSIHR 0.431(0.065) 0.389(0.057) 0.362(0.051) 0.342(0.047) 0.454(0.062)
RRPW 0.454(0.052) 0.399(0.063) 0.329(0.067) 0.236(0.059) 0.444(0.075)
Alternative p1 0.3 0.3 0.5 0.5 0.7
p2 0.7 0.9 0.7 0.9 0.9
Urn RPW 0.341(0.120) 0.227(0.123) 0.411(0.147) 0.288(0.160) 0.375(0.202)
DL 0.363(0.071) 0.290(0.066) 0.424(0.082) 0.343(0.082) 0.416(0.092)
SMLE RWald 0.500(0.104) 0.559(0.100) 0.517(0.100) 0.576(0.099) 0.558(0.101)
RRisk 0.334(0.124) 0.238(0.109) 0.411(0.139) 0.298(0.131) 0.375(0.149)
ROdds 0.500(0.098) 0.438(0.109) 0.485(0.095) 0.423(0.107) 0.438(0.109)
RLLR 0.499(0.091) 0.483(0.093) 0.495(0.092) 0.477(0.094) 0.481(0.094)
RRSIHR 0.408(0.107) 0.378(0.103) 0.459(0.106) 0.429(0.105) 0.468(0.101)
RRPW 0.343(0.122) 0.209(0.110) 0.405(0.141) 0.255(0.136) 0.332(0.174)
DBCD RWald 0.500(0.075) 0.585(0.081) 0.525(0.065) 0.607(0.073) 0.584(0.081)
RRisk 0.300(0.104) 0.187(0.083) 0.391(0.118) 0.250(0.108) 0.337(0.130)
ROdds 0.501(0.061) 0.413(0.086) 0.480(0.054) 0.394(0.079) 0.414(0.084)
RLLR 0.500(0.046) 0.524(0.047) 0.508(0.045) 0.532(0.046) 0.527(0.048)
RRSIHR 0.387(0.080) 0.353(0.075) 0.453(0.069) 0.417(0.066) 0.464(0.055)
RRPW 0.317(0.095) 0.157(0.082) 0.386(0.118) 0.201(0.112) 0.284(0.158)
SEU RWald 0.502(0.106) 0.535(0.108) 0.509(0.102) 0.540(0.102) 0.532(0.108)
RRisk 0.365(0.154) 0.280(0.126) 0.437(0.197) 0.337(0.171) 0.411(0.212)
ROdds 0.453(0.134) 0.384(0.131) 0.469(0.150) 0.399(0.146) 0.438(0.177)
RLLR 0.500(0.091) 0.493(0.094) 0.498(0.093) 0.490(0.094) 0.490(0.092)
RRSIHR 0.449(0.126) 0.429(0.121) 0.479(0.124) 0.460(0.117) 0.481(0.109)
RRPW 0.408(0.162) 0.326(0.141) 0.456(0.197) 0.366(0.173) 0.423(0.208)
GDL RWald 0.499(0.047) 0.548(0.052) 0.514(0.041) 0.562(0.046) 0.548(0.051)
RRisk 0.319(0.104) 0.220(0.078) 0.397(0.128) 0.274(0.104) 0.356(0.138)
ROdds 0.431(0.064) 0.327(0.072) 0.447(0.071) 0.342(0.080) 0.390(0.102)
RLLR 0.500(0.026) 0.485(0.027) 0.495(0.025) 0.479(0.026) 0.483(0.028)
RRSIHR 0.423(0.056) 0.398(0.052) 0.466(0.052) 0.440(0.046) 0.472(0.038)
RRPW 0.367(0.082) 0.263(0.073) 0.420(0.098) 0.303(0.092) 0.370(0.121)
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Type I error of test statistics
Target Method TMW TRISK TMO TMC TML Row Mean
SMLE 4.4(1.1) 4.6(4.1) 2.0(1.4) 5.0(0.6) 6.8(0.9) 4.6(2.4)
DBCD 4.3(1.4) 5.1(5.1) 1.7(1.7) 4.8(1.2) 7.2(0.8) 4.6(2.9)
RWald SEU 4.0(0.9) 3.4(2.4) 2.3(1.2) 4.8(0.2) 5.6(0.6) 4.0(1.7)
GDL 4.4(0.8) 3.7(3.1) 2.1(1.6) 5.2(0.4) 6.6(1.0) 4.4(2.2)
Mean 4.3(1.0) 4.2(3.6) 2.0(1.4) 5.0(0.7) 6.5(1.0) 4.4(2.3)
SMLE 4.4(1.4) 8.6(3.5) 2.4(1.8) 5.5(1.4) 6.0(1.0) 5.4(2.8)
DBCD 4.6(2.0) 10.2(4.4) 2.6(2.3) 5.7(2.2) 6.5(1.4) 5.9(3.5)
RRisk SEU 3.7(0.8) 7.6(2.3) 2.1(0.8) 5.4(1.3) 5.1(0.4) 4.8(2.2)
GDL 4.2(1.3) 7.9(2.4) 2.4(1.9) 5.4(1.6) 5.8(1.4) 5.1(2.5)
Mean 4.2(1.3) 8.6(3.1) 2.4(1.7) 5.5(1.5) 5.9(1.2) 5.3(2.8)
SMLE 3.7(0.6) 2.4(0.5) 2.9(0.5) 4.8(0.4) 4.5(0.4) 3.7(1.0)
DBCD 3.6(0.7) 2.1(0.8) 3.1(0.7) 4.7(0.3) 4.1(0.2) 3.5(1.1)
ROdds SEU 3.6(0.5) 3.6(0.8) 2.3(0.7) 4.7(0.3) 4.9(0.7) 3.8(1.1)
GDL 3.7(0.8) 3.4(0.8) 3.0(1.1) 5.1(0.4) 4.5(0.4) 3.9(1.0)
Mean 3.7(0.6) 2.9(0.9) 2.8(0.8) 4.9(0.4) 4.5(0.5) 3.7(1.1)
SMLE 4.0(0.6) 2.7(1.2) 2.7(1.0) 5.0(0.2) 5.2(0.6) 3.9(1.3)
DBCD 4.2(0.8) 3.3(2.6) 2.4(1.5) 5.0(0.4) 6.1(0.8) 4.2(1.9)
RLLR SEU 4.0(0.6) 2.8(1.6) 2.4(1.0) 4.9(0.2) 5.4(0.8) 3.9(1.5)
GDL 3.7(0.5) 2.5(1.3) 2.7(1.2) 4.9(0.4) 5.4(0.9) 3.8(1.5)
Mean 3.9(0.6) 2.8(1.6) 2.5(1.1) 5.0(0.3) 5.6(0.8) 4.0(1.5)
SMLE 4.2(1.1) 6.2(4.0) 2.3(1.5) 5.2(0.8) 6.1(0.7) 4.8(2.4)
DBCD 4.3(1.5) 6.9(5.2) 2.0(1.6) 5.2(1.3) 6.5(1.1) 5.0(3.0)
RRSIHR SEU 3.9(0.8) 4.8(3.4) 2.3(1.0) 4.8(0.4) 5.5(0.5) 4.3(1.9)
GDL 4.3(0.9) 4.7(3.0) 2.2(1.6) 5.1(0.6) 6.1(0.9) 4.5(2.0)
Mean 4.2(1.0) 5.7(3.8) 2.2(1.3) 5.1(0.8) 6.1(0.8) 4.6(2.3)
RPW 4.2(0.8) 6.2(0.5) 2.5(1.6) 5.5(1.4) 5.4(0.8) 4.8(1.7)
DL 4.3(0.8) 4.8(1.0) 2.6(1.7) 5.3(0.9) 5.3(0.4) 4.5(1.4)
SMLE 4.2(0.9) 6.5(0.6) 2.8(1.8) 5.4(1.6) 5.1(0.8) 4.8(1.7)
RRPW DBCD 4.3(0.9) 6.7(1.0) 2.9(2.1) 5.7(1.8) 4.8(1.0) 4.9(1.9)
SEU 3.8(0.6) 5.7(1.3) 2.2(0.6) 5.4(0.8) 5.1(0.6) 4.5(1.5)
GDL 4.0(0.8) 5.1(0.6) 2.7(1.6) 5.2(0.7) 5.0(0.8) 4.4(1.3)
Mean 4.1(0.8) 5.8(1.1) 2.6(1.5) 5.4(1.2) 5.1(0.7) 4.6(1.6)
Equal Allocation 4.0(0.5) 2.9(1.7) 2.4(1.0) 5.0(0.2) 5.6(0.8) 4.0(1.5)
Power of test statistics
Target Method TMW TRISK TMO TMC TML Row Mean
SMLE 56.6(34.1) 48.6(35.2) 48.5(36.8) 57.6(33.4) 59.4(31.9) 54.2(33.2)
DBCD 56.9(34.4) 49.5(35.9) 48.0(37.6) 57.7(33.9) 60.2(31.8) 54.5(33.7)
RWald SEU 56.0(34.0) 47.7(34.8) 49.6(36.1) 57.5(33.0) 58.4(32.3) 53.8(32.9)
GDL 57.3(34.0) 50.0(36.2) 50.6(36.9) 58.4(33.2) 60.0(32.0) 55.3(33.3)
Mean 56.7(32.8) 49.0(34.2) 49.2(35.4) 57.8(32.1) 59.5(30.7) 54.4(33.0)
SMLE 53.4(33.2) 57.9(31.5) 45.4(35.2) 56.2(32.7) 55.1(31.1) 53.6(31.7)
DBCD 53.3(33.4) 60.0(30.5) 43.7(36.0) 56.5(32.9) 55.0(31.1) 53.7(31.9)
RRisk SEU 52.5(32.8) 55.3(32.2) 45.9(34.1) 55.2(32.1) 54.2(31.2) 52.6(31.3)
GDL 53.2(33.3) 58.1(31.6) 45.8(35.8) 56.5(32.6) 55.2(31.7) 53.8(31.9)
Mean 53.1(31.9) 57.8(30.3) 45.2(33.9) 56.1(31.3) 54.9(30.1) 53.4(31.5)
SMLE 54.6(33.9) 47.1(34.3) 52.1(34.9) 57.6(32.6) 56.4(32.9) 53.6(32.5)
DBCD 54.8(34.2) 47.3(35.2) 53.4(34.5) 57.8(32.7) 56.5(33.4) 53.9(32.8)
ROdds SEU 54.8(33.5) 50.8(33.8) 50.4(34.8) 57.5(32.5) 56.6(32.2) 54.0(32.1)
GDL 54.6(34.2) 53.0(34.6) 52.5(35.0) 58.1(32.7) 56.8(33.0) 55.0(32.5)
Mean 54.7(32.6) 49.5(33.2) 52.1(33.4) 57.8(31.4) 56.6(31.6) 54.1(32.3)
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man’s urn design is studied for both continuous and dis-
continuous outcomes [11,16,17,36]. It is shown that,
under reasonable assumption about the delay, the
asymptotic properties of adaptive design are not affected
by the delay. In the present study, the primary focus is
the comparison between commonly used test statistics
for 2 × 2 tables. Based on results not shown here, a less
extreme allocation with higher variation would be
expected when a random delay is assumed. It is
assumed that the response status of each of the patients
already in the trial is available before the allocation of a
new patient in our simulations evaluation.
The RAR methods simulated in the present study are
aimed at assigning patients to the better treatment with
probabilities higher than what otherwise would be
allowed by equal randomization. The price being paid is
that the sample sizes on the two comparing arms are no
longer fixed, and the adaptation in patient allocation
can complicate the statistical inference at the end of the
trial. The properties of test statistics will change when
the patient allocation ratio changes in adaptive randomi-
zation. The power of test statistics shown in the present
simulation study is obtained by averaging over trials
with an unknown distribution of allocation ratios. As
shown in our simulation results, a large deviation from
the nominal significance level of the hypothesis test can
be found even under the null hypothesis. Therefore, the
practice of comparing asymptotic hypothesis testing
methods based solely on statistical power under the
alternative hypothesis is not recommended. It is
important to compare adaptive randomization methods
based on both the type I error rate and the statistical
power, especially when the sample size is small.
General recommendations given in the result section
are based on the aggregated results across different set-
tings. Because the performance of different test statistics,
RAR methods, and allocation target are closely related
to each other, recommendations under a specific sce-
nario can be found based on the detailed simulation
results in Tables 7, 8, 9, 10, 11, 12.
Based on simulation results, the Cook’s correction to
chi-square test statistic TMC and Williams’ correction to
log-likelihood-ratio test TML are recommended to be
used for hypothesis testing at the end of adaptive rando-
mization. TMC has good ability to attain the correct sig-
nificance levels, and is relatively robust against the
change of RAR method or allocation target. TML has
more robust performance than TMC and has higher
power, but its type I error is slightly inflated as com-
pared with TMC.H o w e v e r ,TML attains more accurate
type I error than TMC when the sample size is small.
The original Wald-type Z test statistic TWald,w h i c hi s
very sensitive to patient allocation and has inflated type
I error, should be avoided at small sample sizes. On the
other hand, TMW, the Argresti’s correction to TWald, and
TMO the modified log-odds-ratio test are too conserva-
tive and under powered at small sample sizes.
The primary objective of current study is to compare
test statistics. Since the recommended test statistics are
TMC and TML, the comparison between RAR methods
and allocation targets are mainly based on these two
Table 6: The mean and standard deviation (in parenthesis) of type I error and power (Continued)
SMLE 55.9(33.9) 48.4(35.0) 51.6(35.6) 58.0(32.8) 58.0(32.6) 54.4(32.8)
DBCD 57.2(34.0) 49.9(35.9) 51.4(36.6) 58.6(33.1) 60.0(32.2) 55.4(33.2)
RLLR SEU 56.1(33.9) 48.5(34.8) 51.2(35.7) 58.1(32.8) 58.2(32.5) 54.4(32.8)
GDL 56.4(34.1) 50.4(35.8) 53.1(35.9) 58.9(33.1) 59.5(32.5) 55.7(33.1)
Mean 56.4(32.6) 49.3(34.0) 51.8(34.6) 58.4(31.7) 58.9(31.2) 55.0(32.7)
SMLE 56.0(33.9) 54.8(33.7) 48.7(36.4) 57.5(33.2) 58.4(32.0) 55.1(32.6)
DBCD 56.8(34.0) 56.3(33.4) 48.2(37.0) 58.2(33.2) 59.4(31.8) 55.7(32.8)
RRSIHR SEU 54.5(33.8) 50.5(34.5) 48.6(35.8) 56.4(33.0) 56.6(32.4) 53.3(32.7)
GDL 57.4(33.7) 54.4(34.5) 50.6(36.6) 58.7(33.0) 59.7(32.1) 56.2(32.8)
Mean 56.2(32.6) 54.0(32.8) 49.0(35.0) 57.7(31.8) 58.5(30.8) 55.1(32.5)
RPW 52.4(32.3) 55.9(32.1) 46.3(34.1) 55.8(32.1) 52.9(30.1) 52.7(31.0)
DL 56.0(33.5) 55.9(33.4) 50.0(36.1) 58.2(32.6) 57.4(32.5) 55.5(32.4)
SMLE 51.7(32.3) 56.2(31.8) 46.7(33.7) 55.7(31.9) 51.7(30.2) 52.4(30.9)
RRPW DBCD 51.2(31.8) 57.3(31.2) 47.0(34.1) 56.0(31.5) 48.3(29.2) 52.0(30.6)
SEU 54.0(33.1) 54.0(32.7) 48.3(34.4) 56.7(32.1) 55.9(31.7) 53.8(31.6)
GDL 54.6(33.5) 56.0(33.0) 50.2(35.3) 57.8(32.4) 56.4(32.3) 55.0(32.0)
Mean 53.3(31.4) 55.9(31.0) 48.1(33.2) 56.7(30.7) 53.8(29.8) 53.5(31.2)
Equal Allocation 56.2(33.9) 48.5(35.0) 50.9(35.9) 58.1(32.9) 58.4(32.4) 54.4(32.9)
Mean values are calculated by averaging simulation results over the five null cases and the ten alternative cases of simulation scenarios listed in Tables 7-12. All
results have been multiplied by 100% (alpha = 0.05, n = 30).
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p1 0.200 0.300 0.500 0.700 0.800 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.200 0.300 0.500 0.700 0.800 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
TMW 0.031 0.048 0.056 0.050 0.033 0.196 0.674 0.953 0.999 0.201 0.600 0.950 0.203 0.680 0.202
TRisk 0.102 0.072 0.039 0.014 0.003 0.326 0.693 0.940 0.996 0.181 0.501 0.798 0.113 0.288 0.024
SMLE TMO 0.007 0.022 0.041 0.024 0.007 0.063 0.492 0.928 0.999 0.162 0.563 0.923 0.161 0.495 0.069
TMC 0.044 0.052 0.056 0.055 0.044 0.231 0.689 0.954 0.999 0.203 0.601 0.952 0.205 0.693 0.235
TML 0.074 0.066 0.055 0.067 0.079 0.308 0.709 0.954 0.999 0.203 0.595 0.951 0.205 0.711 0.309
TMW 0.029 0.050 0.057 0.052 0.026 0.186 0.685 0.957 0.999 0.212 0.607 0.958 0.206 0.696 0.191
TRisk 0.120 0.085 0.041 0.008 0.001 0.361 0.721 0.954 0.998 0.204 0.524 0.811 0.109 0.257 0.010
DBCD TMO 0.004 0.017 0.045 0.017 0.003 0.041 0.462 0.933 0.999 0.169 0.587 0.934 0.164 0.475 0.042
TMC 0.037 0.056 0.058 0.056 0.034 0.211 0.696 0.958 0.999 0.215 0.607 0.959 0.208 0.706 0.215
TML 0.077 0.074 0.059 0.073 0.077 0.311 0.718 0.958 0.999 0.217 0.607 0.959 0.210 0.727 0.315
TMW 0.031 0.045 0.048 0.044 0.030 0.200 0.655 0.946 0.999 0.190 0.583 0.948 0.191 0.675 0.213
TRisk 0.067 0.048 0.033 0.016 0.006 0.259 0.646 0.922 0.991 0.154 0.486 0.812 0.114 0.342 0.046
SEU TMO 0.013 0.026 0.039 0.027 0.011 0.094 0.522 0.921 0.999 0.158 0.553 0.926 0.157 0.533 0.095
TMC 0.046 0.051 0.049 0.050 0.046 0.248 0.675 0.949 0.999 0.195 0.585 0.950 0.195 0.698 0.258
TML 0.062 0.055 0.047 0.055 0.062 0.285 0.683 0.947 0.999 0.190 0.577 0.949 0.193 0.710 0.305
TMW 0.036 0.051 0.051 0.049 0.034 0.223 0.696 0.954 1.000 0.195 0.601 0.958 0.200 0.692 0.214
TRisk 0.075 0.060 0.040 0.010 0.001 0.309 0.703 0.949 0.999 0.184 0.543 0.868 0.124 0.304 0.015
GDL TMO 0.007 0.022 0.046 0.023 0.006 0.077 0.549 0.937 0.999 0.167 0.588 0.945 0.169 0.547 0.077
TMC 0.048 0.057 0.051 0.055 0.047 0.260 0.708 0.955 1.000 0.198 0.602 0.960 0.204 0.705 0.253
TML 0.074 0.064 0.052 0.063 0.076 0.319 0.721 0.956 1.000 0.200 0.602 0.960 0.205 0.720 0.314
For each RAR methods, the results of the following 5 test statistics are shown: Agresti’s correction to Wald-type Z test TMW, log-relative-risk test TRisk, Gart’s
correction to log-odds-ratio test TMO, Cook’s correction to chi-square test TMC, and Williams’ correction log-likelihood-ratio test TML.
Table 8 Power and type I error at RRisk (alpha = 0.05, n = 30)
p1 0.200 0.300 0.500 0.700 0.800 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.200 0.300 0.500 0.700 0.800 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
TMW 0.024 0.045 0.061 0.051 0.041 0.156 0.615 0.923 0.990 0.185 0.560 0.898 0.189 0.611 0.214
TRisk 0.136 0.105 0.078 0.061 0.050 0.363 0.716 0.945 0.997 0.230 0.588 0.923 0.206 0.612 0.210
SMLE TMO 0.002 0.008 0.032 0.039 0.040 0.022 0.278 0.792 0.988 0.096 0.466 0.903 0.157 0.615 0.220
TMC 0.033 0.047 0.060 0.064 0.068 0.177 0.615 0.923 0.996 0.183 0.570 0.939 0.202 0.701 0.316
TML 0.069 0.071 0.061 0.049 0.051 0.278 0.659 0.921 0.975 0.195 0.543 0.883 0.179 0.621 0.253
TMW 0.018 0.046 0.072 0.054 0.042 0.134 0.617 0.931 0.993 0.198 0.565 0.896 0.199 0.586 0.207
TRisk 0.166 0.123 0.091 0.066 0.062 0.402 0.744 0.951 0.998 0.253 0.606 0.926 0.225 0.649 0.243
DBCD TMO 0.001 0.003 0.030 0.046 0.049 0.004 0.164 0.746 0.994 0.074 0.457 0.904 0.158 0.623 0.248
TMC 0.023 0.047 0.070 0.068 0.077 0.148 0.612 0.928 0.998 0.193 0.575 0.940 0.218 0.707 0.327
TML 0.071 0.083 0.071 0.050 0.050 0.278 0.665 0.928 0.979 0.207 0.549 0.880 0.184 0.596 0.240
TMW 0.026 0.039 0.045 0.043 0.032 0.172 0.598 0.903 0.988 0.178 0.537 0.888 0.183 0.606 0.198
TRisk 0.105 0.092 0.075 0.059 0.049 0.307 0.686 0.935 0.996 0.201 0.546 0.903 0.186 0.581 0.193
SEU TMO 0.009 0.018 0.029 0.027 0.023 0.062 0.372 0.794 0.986 0.121 0.468 0.887 0.146 0.582 0.176
TMC 0.041 0.044 0.050 0.064 0.070 0.209 0.605 0.903 0.994 0.178 0.542 0.922 0.194 0.681 0.289
TML 0.057 0.052 0.047 0.049 0.048 0.266 0.640 0.900 0.981 0.183 0.526 0.879 0.178 0.624 0.245
TMW 0.023 0.043 0.059 0.047 0.038 0.168 0.617 0.929 0.993 0.182 0.558 0.902 0.196 0.580 0.195
TRisk 0.113 0.092 0.076 0.062 0.053 0.347 0.720 0.950 0.998 0.227 0.593 0.928 0.220 0.617 0.213
GDL TMO 0.001 0.006 0.031 0.040 0.042 0.016 0.283 0.831 0.994 0.094 0.473 0.908 0.161 0.604 0.220
TMC 0.030 0.047 0.058 0.064 0.070 0.194 0.618 0.928 0.998 0.180 0.567 0.943 0.214 0.696 0.311
TML 0.077 0.068 0.058 0.044 0.045 0.292 0.653 0.927 0.990 0.189 0.540 0.901 0.182 0.606 0.236
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Page 10 of 14Table 9 Power and type I error at ROdds (alpha = 0.05, n = 30)
p1 0.200 0.300 0.500 0.700 0.800 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.200 0.300 0.500 0.700 0.800 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
TMW 0.030 0.040 0.042 0.040 0.031 0.202 0.630 0.935 0.998 0.178 0.562 0.939 0.174 0.637 0.205
TRisk 0.022 0.023 0.030 0.026 0.017 0.143 0.502 0.857 0.984 0.128 0.475 0.884 0.129 0.497 0.112
SMLE TMO 0.024 0.031 0.036 0.031 0.023 0.163 0.587 0.926 0.999 0.154 0.536 0.929 0.151 0.598 0.167
TMC 0.053 0.048 0.043 0.047 0.052 0.283 0.682 0.946 0.999 0.184 0.566 0.947 0.180 0.690 0.285
TML 0.048 0.045 0.040 0.044 0.049 0.266 0.662 0.938 0.998 0.174 0.551 0.941 0.171 0.672 0.270
TMW 0.029 0.040 0.044 0.040 0.028 0.191 0.632 0.940 0.999 0.180 0.572 0.941 0.178 0.644 0.198
TRisk 0.011 0.018 0.032 0.026 0.018 0.085 0.448 0.864 0.994 0.120 0.490 0.906 0.141 0.547 0.134
DBCD TMO 0.026 0.033 0.042 0.031 0.024 0.178 0.609 0.934 0.999 0.165 0.555 0.933 0.161 0.619 0.185
TMC 0.052 0.046 0.045 0.046 0.048 0.280 0.688 0.948 0.999 0.185 0.573 0.949 0.181 0.696 0.284
TML 0.040 0.043 0.043 0.043 0.038 0.244 0.667 0.945 0.999 0.178 0.565 0.944 0.174 0.680 0.252
TMW 0.032 0.041 0.043 0.037 0.030 0.207 0.647 0.935 0.996 0.183 0.562 0.924 0.186 0.636 0.204
TRisk 0.047 0.040 0.035 0.032 0.028 0.214 0.605 0.903 0.993 0.152 0.503 0.894 0.140 0.528 0.146
SEU TMO 0.014 0.026 0.032 0.023 0.020 0.127 0.540 0.900 0.995 0.148 0.520 0.914 0.150 0.587 0.159
TMC 0.049 0.047 0.043 0.047 0.052 0.268 0.676 0.938 0.998 0.187 0.564 0.945 0.191 0.695 0.284
TML 0.059 0.049 0.042 0.044 0.049 0.285 0.677 0.935 0.995 0.182 0.551 0.922 0.183 0.665 0.268
TMW 0.029 0.037 0.049 0.041 0.030 0.203 0.657 0.943 0.999 0.167 0.573 0.929 0.178 0.617 0.192
TRisk 0.024 0.032 0.046 0.035 0.031 0.183 0.625 0.936 0.999 0.158 0.560 0.922 0.165 0.583 0.166
GDL TMO 0.013 0.026 0.043 0.034 0.033 0.124 0.587 0.930 0.999 0.150 0.552 0.928 0.161 0.619 0.204
TMC 0.051 0.047 0.050 0.050 0.058 0.281 0.700 0.948 0.999 0.177 0.579 0.949 0.187 0.695 0.298
TML 0.050 0.047 0.046 0.039 0.043 0.282 0.700 0.947 0.999 0.176 0.563 0.933 0.169 0.652 0.258
Table 10 Power and type I error at RLLR (alpha = 0.05, n = 30)
p1 0.200 0.300 0.500 0.700 0.800 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.200 0.300 0.500 0.700 0.800 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
TMW 0.034 0.043 0.046 0.044 0.031 0.212 0.659 0.946 0.999 0.187 0.575 0.948 0.182 0.667 0.218
TRisk 0.039 0.034 0.033 0.022 0.008 0.203 0.597 0.911 0.995 0.146 0.490 0.869 0.124 0.432 0.072
SMLE TMO 0.018 0.029 0.040 0.031 0.017 0.129 0.577 0.931 0.999 0.162 0.549 0.934 0.156 0.587 0.133
TMC 0.052 0.050 0.046 0.052 0.051 0.274 0.692 0.951 0.999 0.192 0.578 0.953 0.185 0.700 0.278
TML 0.060 0.050 0.044 0.051 0.057 0.289 0.691 0.948 0.999 0.186 0.567 0.950 0.181 0.698 0.289
TMW 0.036 0.047 0.050 0.045 0.031 0.223 0.688 0.957 0.999 0.192 0.591 0.956 0.192 0.697 0.225
TRisk 0.063 0.049 0.037 0.012 0.001 0.278 0.686 0.947 0.998 0.171 0.528 0.872 0.129 0.356 0.026
DBCD TMO 0.010 0.028 0.046 0.026 0.009 0.094 0.569 0.946 0.999 0.169 0.579 0.942 0.171 0.580 0.094
TMC 0.050 0.055 0.051 0.052 0.044 0.265 0.710 0.959 0.999 0.197 0.592 0.959 0.197 0.715 0.267
TML 0.071 0.062 0.051 0.057 0.066 0.315 0.727 0.960 0.999 0.198 0.591 0.959 0.199 0.733 0.316
TMW 0.034 0.043 0.046 0.043 0.033 0.215 0.665 0.947 0.999 0.187 0.581 0.947 0.186 0.671 0.214
TRisk 0.047 0.038 0.031 0.018 0.007 0.226 0.617 0.915 0.995 0.148 0.492 0.854 0.125 0.414 0.063
SEU TMO 0.016 0.027 0.038 0.028 0.013 0.124 0.573 0.931 0.999 0.161 0.553 0.929 0.157 0.574 0.123
TMC 0.052 0.049 0.047 0.050 0.050 0.276 0.696 0.952 0.999 0.191 0.583 0.951 0.191 0.701 0.270
TML 0.063 0.051 0.044 0.052 0.061 0.294 0.696 0.949 0.999 0.186 0.573 0.948 0.186 0.701 0.292
TMW 0.033 0.037 0.043 0.038 0.032 0.230 0.670 0.950 1.000 0.178 0.585 0.956 0.177 0.675 0.215
TRisk 0.035 0.032 0.036 0.018 0.005 0.230 0.645 0.937 0.999 0.151 0.537 0.905 0.139 0.449 0.049
GDL TMO 0.016 0.030 0.043 0.031 0.014 0.139 0.614 0.945 1.000 0.172 0.582 0.951 0.172 0.612 0.127
TMC 0.052 0.050 0.044 0.048 0.053 0.293 0.719 0.955 1.000 0.189 0.588 0.960 0.186 0.722 0.275
TML 0.063 0.051 0.044 0.049 0.064 0.322 0.722 0.955 1.000 0.189 0.587 0.960 0.187 0.728 0.302
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Page 11 of 14selected test statistics. Among SMLE, DBCD, SEU, and
GDL methods, GDL seems to be the best one due to its
ability to attain the correct size of hypothesis test and
comparatively higher overall power at most allocation
targets. Therefore, GDL is the recommended RAR
method. The sequential estimation-adjusted urn (SEU)
method is comparable with GDL in controlling the type
I error. However, SEU is often under powered, and the
high variation in patient allocation makes it less useful
in practice. The DBCD method with tuning exponent a
equal to 2 is the best in targeting the true allocation
ratio. When TMC is the test statistic, DBCD has slightly
inflated type I error and slightly lower power as com-
pared with GDL. Therefore, among values of a,t h eb a l -
ances among controlling the type I error, obtaining
higher power, and targeting a given allocation ratio can
be reached when a is equal to 2. The simulation com-
parison of statistical power for different RAR methods
also indicates that DL urn has the best statistical proper-
ties at RRPW, mainly due to its low variation in patient
allocation.
The statistical characteristics of hypothesis tests and
RAR methods also depend on allocation targets. At
RWald, ROdds,a n dRLLR targets, more patients could be
assigned to the inferior treatment in certain parameter
spaces. In contrast, RRisk, RRPW, and RRSIHR always assign
more patients to the better treatment. However, due to
the more extreme allocation of RRisk and RRPW,b o t h
power and type I error of RRisk and RRPW will suffer as
compared with RRSIHR. On the other hand, the variation
of patient allocation at RRISHR is relatively small with a
stable value across all simulation scenarios. Additional,
among all designs with similar power using Wald-type
test statistic, RRSIHR allocation ration can achieve fewer
failures in the whole trial. Therefore, RRSIHR is recom-
mended among all the allocation targets in the present
study.
In addition to the frequentist development on the
response adaptive randomization, Bayesian decision the-
oretic methods has also been proposed in the context of
bandit problem. The concept of “patient horizon” was
brought up to include future patients to whom the cur-
rent study results might be applied. The goal is to maxi-
mize the total number of success in patients enrolled in
the study with or without including the patient horizon.
More detailed exposition of Bayesian methods for
response adaptive randomization is beyond the scope of
this paper and interested readers should consult the
original work on this topic [37-40].
Conclusion
The Cook’s correction to chi-square test and Williams’
correction to log-likelihood-ratio test are recommended
for hypothesis test of RAR at small sample sizes. Among
all the RAR methods compared, GDL method has better
statistical properties in controlling type one error and
Table 11 Power and type I error at RRSIHR (alpha = 0.05, n = 30)
p1 0.200 0.300 0.500 0.700 0.800 0.100 0.100 0.100 0.100 0.300 0.300 0.300 0.500 0.500 0.700
p2 0.200 0.300 0.500 0.700 0.800 0.300 0.500 0.700 0.900 0.500 0.700 0.900 0.700 0.900 0.900
TMW 0.028 0.045 0.056 0.048 0.035 0.174 0.648 0.944 0.999 0.192 0.588 0.946 0.202 0.678 0.228
TRisk 0.118 0.085 0.058 0.034 0.018 0.343 0.712 0.950 0.999 0.207 0.568 0.910 0.172 0.515 0.102
SMLE TMO 0.004 0.012 0.040 0.034 0.023 0.037 0.397 0.890 0.998 0.130 0.538 0.936 0.170 0.616 0.156
TMC 0.038 0.049 0.056 0.057 0.057 0.200 0.657 0.945 0.999 0.192 0.591 0.953 0.208 0.718 0.290
TML 0.070 0.065 0.056 0.054 0.062 0.291 0.685 0.945 0.998 0.196 0.579 0.946 0.197 0.705 0.301
TMW 0.020 0.050 0.057 0.050 0.038 0.157 0.654 0.948 0.999 0.201 0.605 0.956 0.217 0.700 0.242
TRisk 0.138 0.103 0.062 0.030 0.013 0.383 0.732 0.953 0.999 0.227 0.594 0.922 0.186 0.534 0.097
DBCD TMO 0.001 0.007 0.038 0.034 0.020 0.017 0.323 0.887 0.999 0.123 0.554 0.942 0.185 0.628 0.159
TMC 0.028 0.056 0.057 0.057 0.060 0.183 0.662 0.948 0.999 0.202 0.607 0.959 0.221 0.733 0.304
TML 0.074 0.079 0.057 0.052 0.064 0.293 0.693 0.948 0.999 0.208 0.593 0.954 0.207 0.726 0.317
TMW 0.029 0.039 0.050 0.044 0.033 0.181 0.626 0.930 0.998 0.178 0.559 0.932 0.182 0.653 0.214
TRisk 0.095 0.070 0.044 0.024 0.010 0.275 0.650 0.926 0.996 0.163 0.512 0.875 0.137 0.449 0.071
SEU TMO 0.014 0.021 0.037 0.028 0.016 0.075 0.466 0.892 0.997 0.137 0.521 0.921 0.152 0.574 0.128
TMC 0.044 0.045 0.050 0.053 0.049 0.225 0.642 0.932 0.998 0.181 0.562 0.945 0.189 0.696 0.271
TML 0.058 0.053 0.050 0.052 0.062 0.268 0.657 0.929 0.997 0.178 0.548 0.934 0.179 0.684 0.289
TMW 0.031 0.048 0.052 0.050 0.036 0.206 0.682 0.951 1.000 0.197 0.610 0.961 0.212 0.690 0.235
TRisk 0.084 0.065 0.050 0.026 0.009 0.321 0.715 0.952 1.000 0.201 0.591 0.919 0.173 0.495 0.076
GDL TMO 0.002 0.016 0.042 0.034 0.017 0.047 0.476 0.923 1.000 0.147 0.577 0.947 0.186 0.613 0.142
TMC 0.040 0.052 0.052 0.056 0.053 0.228 0.689 0.952 1.000 0.198 0.611 0.964 0.216 0.721 0.289
TML 0.074 0.062 0.051 0.055 0.063 0.301 0.707 0.952 1.000 0.199 0.602 0.962 0.207 0.722 0.316
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Page 12 of 14maintaining high statistical power. The RSIHR allocation
target provides a good balance between assigning more
patients to the better treatment and maintaining a high
overall power.
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